Clinical Trials · NCT02799602
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Bayer
- Enrollment
- 1,306
- Start date
- Nov 2016
- Locations
- 322 sites, 23 countries
- Primary endpoint
- OS From Date of Randomization Until Death From Any Cause - Number of Events